Jazz extends $1.9B term loan to 2033, cuts margin by 50 bps

Jazz Pharmaceuticals plc

Jazz Lux amended credit agreement to extend $1,895,000,000 term loans maturity from May 5, 2028 to May 5, 2033.
Interest margin reduced by 50 bps: now Term SOFR + 1.75% or prime + 0.75%, with 0.50% SOFR floor.
Borrowed $273,310,355.18 new Tranche B-3 loans to repay non-converted Tranche B-2 loans; total principal unchanged at $1,895,000,000.
Loans amortize quarterly at 0.25% of initial principal, balance due at new 2033 maturity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.